{"id":56798,"date":"2026-02-10T23:26:52","date_gmt":"2026-02-10T15:26:52","guid":{"rendered":"https:\/\/flcube.com\/?p=56798"},"modified":"2026-02-10T23:26:53","modified_gmt":"2026-02-10T15:26:53","slug":"nanjing-hanxin-licenses-ac02-acth-analogue-to-amphastar-for-151-million-us-canada-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56798","title":{"rendered":"Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US\/Canada Deal"},"content":{"rendered":"\n

Nanjing Hanxin Pharmaceutical Technology Co., Ltd.<\/strong> has entered a licensing agreement<\/strong> with Amphastar Pharmaceuticals, Inc.<\/strong> (NASDAQ: AMPH<\/a>), granting the US-based specialty pharma company exclusive development and commercialization rights<\/strong> to AC02<\/strong>, a fully synthetic, high-purity adrenocorticotropic hormone (ACTH) analogue<\/strong>, in the United States and Canada<\/strong>. The transaction, valued at USD 151 million<\/strong>, marks a significant validation of Chinese peptide synthesis capabilities<\/strong> in the North American specialty endocrine market.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (China)<\/td><\/tr>
Licensee<\/strong><\/td>Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)<\/td><\/tr>
Asset<\/strong><\/td>AC02 \u2013 Fully synthetic, high-purity ACTH analogue<\/td><\/tr>
Territory<\/strong><\/td>United States and Canada (exclusive)<\/td><\/tr>
Deal Value<\/strong><\/td>USD 151 million<\/strong> (additional terms undisclosed)<\/td><\/tr>
Therapeutic Class<\/strong><\/td>Synthetic peptide hormone replacement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Competitive Positioning<\/h2>\n\n\n\n
Feature<\/th>AC02 Specification<\/th>Market Context<\/th><\/tr><\/thead>
Structure<\/strong><\/td>Fully synthetic ACTH analogue<\/strong><\/td>Addresses supply chain and purity concerns with animal-derived ACTH<\/td><\/tr>
Purity Profile<\/strong><\/td>High-purity synthetic manufacturing<\/strong><\/td>Reduces immunogenicity risk vs. porcine-derived alternatives<\/td><\/tr>
Mechanism<\/strong><\/td>Stimulates adrenal cortex cortisol production<\/td>Established therapeutic class for autoimmune and inflammatory conditions<\/td><\/tr>
Manufacturing<\/strong><\/td>Synthetic chemistry<\/strong> (vs. extraction)<\/td>Scalable, consistent supply; avoids animal sourcing constraints<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Target Indications & Market Opportunity<\/h2>\n\n\n\n
Therapeutic Area<\/th>Current Standard<\/th>AC02 Value Proposition<\/th><\/tr><\/thead>
Infantile Spasms<\/strong><\/td>H.P. Acthar Gel (rare disease, high-cost)<\/td>Synthetic alternative with supply security and pricing flexibility<\/td><\/tr>
Multiple Sclerosis Relapse<\/strong><\/td>Acthar Gel (corticotropin)<\/td>High-purity synthetic may reduce antibody formation and tachyphylaxis<\/td><\/tr>
Rheumatology\/Autoimmune<\/strong><\/td>Off-label Acthar use<\/td>Consistent dosing and reimbursement advantages of synthetic product<\/td><\/tr>
Nephrotic Syndrome<\/strong><\/td>Steroid-resistant cases<\/td>ACTH mechanism distinct from corticosteroids<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n